Key result
Dapagliflozin lowers blood pressure and preserves renal function in elderly patients with diabetes and hypertension.
Why the study?
Older adults with type 2 diabetes and hypertension face increased cardiovascular and renal risks complicated by multimorbidity and polypharmacy, necessitating evaluation of dapagliflozin's efficacy, safety, and practical use in this population.
Dapagliflozin offers valuable cardiorenal protection and blood pressure-lowering benefits in elderly patients with T2DM and hypertension, provided its use is carefully individualized to mitigate risks associated with polypharmacy and volume depletion.
May support individualized dapagliflozin use in elderly T2DM-hypertension; leaves open dedicated geriatric trials for polypharmacy risks.
Older adults with type 2 diabetes mellitus (T2DM) and hypertension are at a substantially increased risk of cardiovascular and renal complications, with disease management often complicated by multimorbidity and polypharmacy. Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, has demonstrated clinical benefits that extend beyond glycaemic control, including improvements in blood pressure, renal outcomes, and cardiovascular health. This review evaluates the current evidence regarding the efficacy, safety, and practical application of dapagliflozin in elderly patients with T2DM and hypertension. Findings from randomized controlled trials, meta-analyses, and real-world studies indicate that dapagliflozin provides effective glycaemic control, slows the progression of chronic kidney disease, and reduces the risk of heart failure and cardiovascular events across older age groups. The review also discusses age-related physiological changes, potential drug interactions, and the challenges associated with polypharmacy, emphasizing the importance of individualized treatment, careful assessment of renal function, and regular monitoring of hydration status. In addition, practical recommendations for treatment initiation, dose optimization, follow-up, and management during acute illness are presented. Overall, dapagliflozin demonstrates a favourable benefit–risk profile and represents a valuable therapeutic option for elderly patients when prescribed with individualized monitoring and appropriate clinical supervision
No takes yet. Share an insight, caveat, or question.
Andhuvan et al. (2026) conducted a review in Type 2 diabetes mellitus and hypertension in older adults. Dapagliflozin was evaluated. Dapagliflozin demonstrates a favorable benefit-risk profile in elderly patients with type 2 diabetes and hypertension, lowering blood pressure and preserving renal function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: